Quick Answer
Denali Therapeutics Inc. reported Total Revenue of $0.00 for fiscal year 2025.
Denali Therapeutics Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $0.00 | $0.00 -100.0% |
$330.53M +204.7% |
$108.46M +122.9% |
$48.66M -85.5% |
$335.66M +1158.2% |
| Revenue (ASC 606) | $0.00 | $0.00 -100.0% |
$330.53M +214.6% |
$105.06M +115.9% |
$48.66M -85.5% |
$335.56M +1174.9% |
| Net Income | -$512.54M -21.2% |
-$422.77M -191.1% |
-$145.22M +55.5% |
-$325.99M -12.2% |
-$290.58M -508.5% |
$71.14M +136.0% |
| Diluted EPS | -$2.97 -15.6% |
-$2.57 -142.5% |
-$1.06 +59.2% |
-$2.60 -8.8% |
-$2.39 -479.4% |
$0.63 +130.4% |
| Total Assets | $1.14B -16.7% |
$1.37B +19.1% |
$1.15B -21.0% |
$1.46B +4.0% |
$1.40B -12.5% |
$1.60B +190.0% |
| Cash and Equivalents | $205.33M +17.4% |
$174.96M +37.6% |
$127.11M -41.7% |
$218.04M -25.7% |
$293.48M -42.1% |
$507.14M +538.3% |
| Stockholders Equity | $1.01B -17.6% |
$1.23B +19.3% |
$1.03B -1.1% |
$1.04B +8.3% |
$962.29M -16.4% |
$1.15B +191.4% |
| R&D Expense | $418.78M +5.6% |
$396.44M -6.5% |
$423.88M +18.2% |
$358.73M +35.2% |
$265.35M +24.8% |
$212.62M +9.9% |
| Operating Income | -$555.34M -14.0% |
-$487.34M -147.8% |
-$196.70M +42.3% |
-$340.74M -15.2% |
-$295.75M -571.6% |
$62.72M +129.4% |
| Shares Outstanding | 156.18M +8.3% |
144.22M +4.2% |
138.39M +1.8% |
135.97M +11.2% |
122.28M +1.5% |
120.53M +25.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2024 | $0.00 | -100.0% | — |
| Revenue (ASC 606) | September 30, 2024 | $0.00 | -100.0% | — |
| Net Income | September 30, 2025 | -$126.90M | -18.4% | -2.2% |
| Diluted EPS | September 30, 2025 | -$0.74 | -17.5% | -2.8% |
| Total Assets | September 30, 2025 | $1.06B | -27.4% | -9.5% |
| Cash and Equivalents | September 30, 2025 | $90.96M | +0.4% | -35.6% |
| Stockholders Equity | September 30, 2025 | $926.20M | -29.8% | -9.8% |
| R&D Expense | September 30, 2025 | $101.95M | +3.8% | -0.7% |
| Operating Income | September 30, 2025 | -$137.43M | -11.6% | -1.8% |
| Shares Outstanding | September 30, 2025 | 146.63M | +1.9% | +0.6% |
- Denali Therapeutics Inc. reported Total Revenue of $0.00 for fiscal year 2025.
- Denali Therapeutics Inc. reported Revenue (ASC 606) of $0.00 for fiscal year 2025.
- Denali Therapeutics Inc. reported Net Income of -$512.54 million for fiscal year 2025.
- Denali Therapeutics Inc. showed a decrease of -21.2% in Net Income compared to the prior fiscal year.
- Denali Therapeutics Inc. reported Diluted EPS of $2.97 per share (loss) for fiscal year 2025.
- Denali Therapeutics Inc. showed a decrease of -15.6% in Diluted EPS compared to the prior fiscal year.
- Denali Therapeutics Inc. reported Total Assets of $1.14 billion for fiscal year 2025.
- Denali Therapeutics Inc. showed a decrease of -16.7% in Total Assets compared to the prior fiscal year.
- Denali Therapeutics Inc. reported Cash and Equivalents of $205.33 million for fiscal year 2025.
- Denali Therapeutics Inc. showed an increase of +17.4% in Cash and Equivalents compared to the prior fiscal year.
- Denali Therapeutics Inc. reported Stockholders Equity of $1.01 billion for fiscal year 2025.
- Denali Therapeutics Inc. showed a decrease of -17.6% in Stockholders Equity compared to the prior fiscal year.
- Denali Therapeutics Inc. reported R&D Expense of $418.78 million for fiscal year 2025.
- Denali Therapeutics Inc. showed an increase of +5.6% in R&D Expense compared to the prior fiscal year.
- Denali Therapeutics Inc. reported Operating Income of -$555.34 million for fiscal year 2025.
- Denali Therapeutics Inc. showed a decrease of -14.0% in Operating Income compared to the prior fiscal year.
- Denali Therapeutics Inc. reported Shares Outstanding of 156.18 million shares for fiscal year 2025.
- Denali Therapeutics Inc. showed an increase of +8.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: